Back to Search Start Over

SGLT6 - A pharmacological target for the treatment of obesity?

Authors :
Baader-Pagler T
Eckhardt M
Himmelsbach F
Sauer A
Stierstorfer BE
Hamilton BS
Source :
Adipocyte [Adipocyte] 2018; Vol. 7 (4), pp. 277-284. Date of Electronic Publication: 2018 Oct 11.
Publication Year :
2018

Abstract

Despite increased knowledge of nutrient intake regulation and energy homeostasis, treatment options for obesity remain limited. Food reward consists of two branches: gustatory and post-ingestive nutritive information. Drosophila lacking dSLC5A11 (sodium/glucose cotransporter 6-SGLT6) prefer L-glucose over D-glucose independently of their state of satiety. Human SGLT6 is an active transporter of myo-inositol and D-glucose. We investigated expression of SGLT6 in human tissue and found a significant expression in the small intestine and brain. The preference between a metabolizable and a non-metabolizable sugar was tested in 3 mouse models with a selective and potent SGLT6 inhibitor. No influence on sugar preference was seen with SGLT6 inhibition. These studies suggest that SGLT6 does not play a significant role in nutrient sensing in mammals.

Details

Language :
English
ISSN :
2162-397X
Volume :
7
Issue :
4
Database :
MEDLINE
Journal :
Adipocyte
Publication Type :
Academic Journal
Accession number :
30161013
Full Text :
https://doi.org/10.1080/21623945.2018.1516098